Regeneron Pharmaceuticals, Inc. (ETR:RGO)
Germany · Delayed Price · Currency is EUR 495.40
+3.10 (0.63%)
At close: Oct 10, 2025
Regeneron Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
| 14,214 | 14,202 | 13,117 | 12,173 | 16,072 | 8,497 | Upgrade | |
Revenue Growth (YoY) | 5.38% | 8.27% | 7.76% | -24.26% | 89.14% | 29.58% | Upgrade |
Cost of Revenue | 2,051 | 1,971 | 1,816 | 1,560 | 2,438 | 1,120 | Upgrade |
Gross Profit | 12,163 | 12,232 | 11,301 | 10,613 | 13,634 | 7,377 | Upgrade |
Selling, General & Admin | 2,774 | 2,954 | 2,631 | 2,116 | 1,825 | 1,346 | Upgrade |
Research & Development | 5,525 | 5,233 | 4,625 | 3,848 | 2,908 | 2,735 | Upgrade |
Other Operating Expenses | -23.5 | -53.4 | 2.1 | 89.9 | 45.6 | 280.4 | Upgrade |
Operating Income | 3,888 | 4,098 | 4,043 | 4,559 | 8,856 | 3,016 | Upgrade |
Interest Expense | -36.6 | -55.2 | -73 | -59.4 | -57.3 | -56.9 | Upgrade |
Other Non-Operating Income (Expense) | 1,071 | 844.4 | 225.2 | 179.3 | 436.3 | 290.7 | Upgrade |
Total Non-Operating Income (Expense) | 1,034 | 789.2 | 152.2 | 119.9 | 379 | 233.8 | Upgrade |
Pretax Income | 4,922 | 4,887 | 4,195 | 4,679 | 9,235 | 3,250 | Upgrade |
Provision for Income Taxes | 416.2 | 367.3 | 245.7 | 520.4 | 1,251 | 297.2 | Upgrade |
Net Income | 4,459 | 4,413 | 3,954 | 4,338 | 8,075 | 3,513 | Upgrade |
Net Income to Common | 4,459 | 4,413 | 3,954 | 4,338 | 8,075 | 3,513 | Upgrade |
Net Income Growth | 3.17% | 11.61% | -8.87% | -46.28% | 129.86% | 66.05% | Upgrade |
Shares Outstanding (Basic) | 107 | 108 | 107 | 107 | 106 | 108 | Upgrade |
Shares Outstanding (Diluted) | 112 | 115 | 114 | 114 | 112 | 115 | Upgrade |
Shares Change (YoY) | -1.75% | 1.23% | 0.18% | 1.16% | -2.52% | 0.44% | Upgrade |
EPS (Basic) | 41.76 | 40.90 | 37.05 | 40.51 | 76.40 | 32.65 | Upgrade |
EPS (Diluted) | 39.73 | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 | Upgrade |
EPS Growth | 5.19% | 10.27% | -9.03% | -46.89% | 135.81% | 65.33% | Upgrade |
Free Cash Flow | 3,854 | 3,665 | 3,875 | 4,425 | 6,529 | 2,004 | Upgrade |
Free Cash Flow Growth | 5.16% | -5.44% | -12.42% | -32.23% | 225.90% | 0.15% | Upgrade |
Free Cash Flow Per Share | 34.29 | 31.84 | 34.08 | 38.99 | 58.19 | 17.41 | Upgrade |
Dividends Per Share | 1.760 | - | - | - | - | - | Upgrade |
Gross Margin | 85.57% | 86.13% | 86.16% | 87.18% | 84.83% | 86.82% | Upgrade |
Operating Margin | 27.35% | 28.85% | 30.82% | 37.45% | 55.10% | 35.49% | Upgrade |
Profit Margin | 31.70% | 31.82% | 30.11% | 34.16% | 49.68% | 34.75% | Upgrade |
FCF Margin | 27.11% | 25.80% | 29.54% | 36.35% | 40.63% | 23.58% | Upgrade |
EBITDA | 4,398 | 4,580 | 4,464 | 4,901 | 9,142 | 3,252 | Upgrade |
EBITDA Margin | 30.94% | 32.25% | 34.03% | 40.26% | 56.88% | 38.27% | Upgrade |
EBIT | 3,888 | 4,098 | 4,043 | 4,559 | 8,856 | 3,016 | Upgrade |
EBIT Margin | 27.35% | 28.85% | 30.82% | 37.45% | 55.10% | 35.49% | Upgrade |
Effective Tax Rate | 8.46% | 7.52% | 5.86% | 11.12% | 13.54% | 9.15% | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.